$1.19
+0.06 (+5.31%)
Open$1.11
Previous Close$1.13
Day High$1.24
Day Low$1.02
52W High$7.36
52W Low$0.74
Volume—
Avg Volume661.6K
Market Cap35.05M
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,745.4% upside
Current
$1.19
$1.19
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.55M | 1.30M | 5.52M |
| Net Income | -168,618,765 | -127,419,721 | -589,967 |
| Profit Margin | -10,887.4% | -10,343.0% | -10.7% |
| EBITDA | -121,009,107 | -96,522,797 | -924,468 |
| Free Cash Flow | — | — | -774,673 |
| Rev Growth | +19.1% | +19.1% | -1.7% |
| Debt/Equity | 1.21 | 1.21 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |